Non-Malignant
Key updates in thalassemia at ASH 2023: gene therapies, ongoing trials & the value of precision medicine
In the last decade, the treatment landscape of thalassemia has been transformed with the introduction of novel therapies. With several…
Date: 31st January 2024
Key updates in sickle cell disease at ASH 2023: disease biology, ongoing trials & the growing role of gene therapy
In recent years, the treatment landscape of sickle cell disease (SCD) has been revolutionized with the introduction of novel agents,…
Date: 12th January 2024
Hemophilia: the current standard of care and the value of novel gene therapies
Over the years, the hemophilia treatment landscape has transformed, with novel agents aiming to improve patient care and quality of…
Date: 5th July 2023
